<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000572133"><TermName>Amevive</TermName><TermPronunciation>(A-meh-veev)</TermPronunciation><TermDefinition><DefinitionText>A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Amevive is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant. Also called alefacept.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720707" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Amevive&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720706" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Amevive&quot;" language="es" id="_4"/><SpanishTermName>Amevive</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar ciertas afecciones de la piel y que está en estudio para el tratamiento del cáncer cutáneo (relacionado con la piel) de células T y el linfoma no Hodgkin de células T. Amevive se elabora combinando parte de un anticuerpo con una proteína que bloquea el crecimiento de algunos tipos de células T. Es un tipo de proteína de fusión y de inmunodepresor. También se llama alefacept.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-10-04</DateFirstPublished><DateLastModified>2008-03-11</DateLastModified></GlossaryTerm>
